This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Retavase

Chiesi Farmaceutici S.p.A.

Drug Names(s): reteplase, Rapilysin

Description: Retavase is a recombinant plasminogen activator which catalyzes the cleavage of endogenous plasminogen to generate plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action.

Deal Structure: PDL and Centocor
Protein Design Labs completed the acquisition of ESP Pharma Holding Company in March 2005. PDL has also completed, through the purchase of ESP Pharma, the acquisition of certain product rights and assets relating to a product known as Retavase from Centocor.

Under the terms of the Retavase acquisition agreement, ESP Pharma paid to Centocor $110 million for the rights to manufacture, develop, market and distribute Retavase in the United States and Canada. Additional milestone payments of up to $45 million will be made if additionalconditions relating to the ongoing clinical trials and manufacturing arrangements are satisfied.

EKR and PDL
In February 2008, EKR Therapeutics and PDL BioPharma announced that they have entered into an agreement under which EKR would acquire the rights to PDL's Cardene I.V. and new formulations of Cardene in development, as well as Retavase (reteplase) and ularitide. Under the terms of the agreement, PDL would...See full deal structure in Biomedtracker

Partners: Johnson & Johnson PDL BioPharma, Inc.


Retavase News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug